AI assistant
N4 PHARMA PLC — Remuneration Information 2018
Mar 9, 2018
7804_dirs_2018-03-09_b9ea2849-d140-4424-8eba-08d48f511406.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
March 9, 2018, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it granted the following options over ordinary shares of £0.05 each (the "Ordinary Shares") and American Depositary Shares ("ADS") and restricted share units ("RSUs") and Restricted American Depositary Share Units ("RADSUs") to directors and employees of Verona Pharma under and in accordance with Verona Pharma's 2017 Incentive Award Plan (which is set out in Verona Pharma's 2017 annual report and 20-F):
-
1,798,767 options to purchase Ordinary Shares;
-
36,510 options to purchase ADSs, representing 292,080 Ordinary Shares;
-
246,570 RSUs; and
-
3,352 RADSUs, representing 26,816 Ordinary Shares.
Each RSU and RADSU represents an unfunded, unsecured right to receive, on the applicable settlement date, one Ordinary Share or the equivalent number of ADSs, as applicable, or an amount in cash or other consideration. Except where the context indicates otherwise, references hereunder to the Ordinary Shares shall be deemed to include a number of ADSs equal to an Ordinary Share. No consideration was paid in respect of the grant of awards.
PDMR Dealings
Verona Pharma notifies the following transactions by persons discharging managerial responsibilities ("PDMRs") in its Ordinary Shares through the grant of options over Ordinary Shares and ADSs and RSUs under and in accordance with Verona Pharma's 2017 Incentive Award Plan.
| Name | Options over | RSUs and RADSUs |
| Dr. Jan-Anders Karlsson | 868,758 Ordinary Shares | 136,986 RSUs |
| Piers Morgan | 304,063 Ordinary Shares | 47,944 RSUs |
| Dr. Ken Newman | 10,316 ADSs (Representing 82,528 Ordinary Shares) |
1,626 RADSUs (Representing 13,008 RSUs) |
The options over Ordinary Shares have an exercise price of £1.46 per Ordinary Share, being the closing mid-market price on March 8, 2017. The options over ADSs have an exercise price of £11.68 per ADS, on the basis that each ADS represents 8 ordinary shares. The RSUs also have a value of £1.46 per RSU and the RADSUs have a value of £11.68 per RADSU.
The options, RSUs and RADSUs set forth in the table above will vest as to 50% of the Ordinary Shares or ADSs (as appropriate) in three substantially equal annual instalments following the grant date and as to 50% of the Ordinary Shares or ADSs (as appropriate) in four substantially equal annual instalments following the grant date.
The notification of dealing form in respect of option/RSU awards for each PDMR can be found below.
For further information, please contact:
Verona Pharma plc
Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer
| Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) | |
| Stewart Wallace / Jonathan Senior / Ben Maddison |
Tel: +44 (0) 20 7710 7600
FTI Consulting (UK Media and Investor enquiries)
Tel: +44 (0)20 3727 1000
Simon Conway / Natalie Garland-Collins
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Dr. Jan-Anders Karlsson | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Executive Officer | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Verona Pharma plc | |
| b) | Legal Entity Identifier | 213800EVI6O6J3TIAL06 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of 5p each | |
| Identification code | ISIN Code: GB00BYW2KH80 | ||
| b) | Nature of the transaction | Issue of options over Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Exercise Price: £1.46 | Options over 868,758 Ordinary Shares | ||
| d) | Aggregated information - Aggregated volume - Price |
N/a (single transaction) | |
| e) | Date of the transaction | 8 March 2018 | |
| f) | Place of the transaction | London Stock Exchange, AIM |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of 5p each | |
| Identification code | ISIN Code: GB00BYW2KH80 | ||
| b) | Nature of transaction | Grant of RSUs, each of which represents an unfunded, unsecured right to receive, on the applicable settlement date, one Ordinary Share or an amount in cash or other consideration | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| No consideration |
136,986 | ||
| d) | Aggregated information - Aggregated volume - Price |
N/a (single transaction) | |
| e) | Date of the transaction | 8 March 2018 | |
| f) | Place of the transaction | London Stock Exchange, AIM |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Piers Morgan | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Financial Officer | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Verona Pharma plc | |
| b) | Legal Entity Identifier | 213800EVI6O6J3TIAL06 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of 5p each | |
| Identification code | ISIN Code: GB00BYW2KH80 | ||
| b) | Nature of the transaction | Issue of options over Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Exercise Price: £1.46 |
Options over 304,063 Ordinary Shares | ||
| d) | Aggregated information - Aggregated volume - Price |
N/a (single transaction) | |
| e) | Date of the transaction | 8 March 2018 | |
| f) | Place of the transaction | London Stock Exchange, AIM |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of 5p each | |
| Identification code | ISIN Code: GB00BYW2KH80 | ||
| b) | Nature of transaction | Grant of RSUs, each of which represents an unfunded, unsecured right to receive, on the applicable settlement date, one Ordinary Share or an amount in cash or other consideration | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| No consideration |
47,944 | ||
| d) | Aggregated information - Aggregated volume - Price |
N/a (single transaction) | |
| e) | Date of the transaction | 8 March 2018 | |
| f) | Place of the transaction | London Stock Exchange, AIM |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Dr. Ken Newman | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Medical Officer | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Verona Pharma plc | |
| b) | Legal Entity Identifier | 213800EVI6O6J3TIAL06 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | American Depositary Shares ("ADSs"), representing ordinary shares of 5p each, on deposit with a U.S. banking institution selected by the Company and which are registered pursuant to a Form F-6. | |
| Identification code | ISIN Code: GB00BYW2KH80 | ||
| b) | Nature of the transaction | Issue of options over ADSs | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Exercise Price: £11.68 |
Options over 10,316 ADSs (representing 82,528 Ordinary Shares) |
||
| d) | Aggregated information - Aggregated volume - Price |
N/a (single transaction) | |
| e) | Date of the transaction | 8 March 2018 | |
| f) | Place of the transaction | NASDAQ |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | ADSs | |
| Identification code | ISIN Code: US9250501064 | ||
| b) | Nature of transaction | Grant of RADSUs, each of which represents an unfunded, unsecured right to receive, on the applicable settlement date, one ADS or an amount in cash or other consideration | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| No consideration |
1,626 (representing 13,008 Ordinary Shares) |
||
| d) | Aggregated information - Aggregated volume - Price |
N/a (single transaction) | |
| e) | Date of the transaction | 8 March 2018 | |
| f) | Place of the transaction | NASDAQ |
*This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Verona Pharma plc via Globenewswire*